2023-08-02 06:20:50 ET
- BeiGene press release ( NASDAQ: BGNE ): Q2 GAAP EPS of -$0.28 beats by $3.25 .
- Revenue of $595.26M (+74.3% Y/Y) beats by $79.9M .
- Global sales of BRUKINSA totaled $308 million in the quarter, a 139% increase from the prior-year period and a 46% increase from the prior quarter; continued execution on launch of BRUKINSA in the U.S. and Europe for the treatment of adult patients with chronic lymphocytic leukemia, strengthening its position as the BTK inhibitor of choice.
- Product Revenue for the three months ended June 30, 2023, was $553.7 million, compared to $304.5 million in the same period of 2022, representing 81.8% growth.
- Gross Margin as a percentage of global product revenue for the second quarter of 2023 was 82.7%, compared to 76.6% in the prior-year period.
For further details see:
BeiGene GAAP EPS of -$0.28 beats by $3.25, revenue of $595.26M beats by $79.9M